In a report by Sarah Faulkner for Drug Delivery Business, Insulet has announced that its Omnipod insulin management system is available in Europe for use with Novo Nordisk’s Fiasp (fast-acting insulin aspart).
Novo Nordisk’s Fiasp product enters the user’s bloodstream two times faster than NovoRapid and is designed to match a healthy body’s response to a meal, according to Insulet.
“The addition of Fiasp for use with the Omnipod System provides another option for both patients and prescribers to support their diabetes management needs,” says DJ Cass, GM of Insulet’s Europe unit. Insulet has a team of more than 100 employees to take care of distributing and selling its Omnipod system in Europe.
Stephen Gough, Novo Nordisk’s global CMO, added. “With its ultra-fast acting profile, Fiasp has brought a new option for adults living with diabetes who require insulin to manage their post-meal spikes, and I am confident that they will find in Fiasp and the Omnipod System good allies to best manage their diabetes.”
News items and features like this appear in the Desang Diabetes Magazine, our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it’s free, and you can easily unsubscribe should you wish to).